• Financial toxicity in BRCA1 and BRCA2 carriers.
    • Proussaloglou EM, Rosenthal AE, Raker CA, Wilbur JS, Stuckey AR, Robison KM.
    • Gynecol Oncol. 2023 Jan 24;170:160-166. doi: 10.1016/j.ygyno.2023.01.007. Epub ahead of print.
    • Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan.
    • Nomura H, Abe A, Fusegi A, Yoshimitsu T, Misaka S, Murakami A, Matsumoto T, Tsumura S, Kanno M, Aoki Y, Netsu S, Omi M, Tanigawa T, Okamoto S, Omatsu K, Yunokawa M, Kanao H, Habano E, Arakawa H, Kaneko K, Ueki A, Haruyama Y, Inari H, Ueno T.
    • Sci Rep. 2023 Jan 19;13(1):1018. doi: 10.1038/s41598-023-28304-w.
    • Environmental impact on carcinogenesis under BRCA1 haploinsufficiency.
    • Toyokuni S, Kong Y, Motooka Y, Akatsuka S.
    • Genes Environ. 2023 Jan 13;45(1):2. doi: 10.1186/s41021-023-00258-5.
    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary
    • Update: Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations.
    • [No author given]
    • FORCE. XRAY. 2023 Jan 9.

    Related:

    •• Identifier: NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)

    • All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    • Wu HL, Luo ZY, He ZL, Gong Y, Mo M, Ming WK, Liu GY.
    • Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02111-y. Epub ahead of print.
    • Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model.
    • Etchegary H, Pike A, Puddester R, Watkins K, Warren M, Francis V, Woods M, Green J, Savas S, Seal M, Gao Z, Avery S, Curtis F, McGrath J, MacDonald D, Burry TN, Dawson L.
    • PLoS One. 2022 Dec 22;17(12):e0279317. doi: 10.1371/journal.pone.0279317.
    • Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
    • Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L, Legood R, Manchanda R.
    • Cancers (Basel). 2022 Dec 12;14(24):6117. doi: 10.3390/cancers14246117.
    • Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment.
    • Wang C, Gao P, Xu J, Liu S, Tian W, Liu J, Zhou L.
    • Front Pharmacol. 2022 Dec 7;13:1078303. doi: 10.3389/fphar.2022.1078303.
    • The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2.
    • Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A, Rosenthal AN.
    • J Med Genet. 2022 Nov 1:jmedgenet-2022-108741. doi: 10.1136/jmg-2022-108741. Epub ahead of print.
    • Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    • Evron E, Ben-David MA, Kaidar-Person O, Corn BW.
    • J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609. Epub ahead of print.
    • Nest Genomics Building EHR-Integrated Clinical Decision Support for Genetics-Informed Care.
    • Cohen JK.
    • GenomeWeb. Disease Areas. Cancer. 2022 Oct 25.
    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • Low-level constitutional mosaicism of BRCA1 in two women with young onset ovarian cancer.
    • Speight B, Colvin E, Epurescu ED, Drummond J, Verhoef S, Pereira M, Evans DG, Tischkowitz M.
    • Hered Cancer Clin Pract. 2022 Sep 6;20(1):32. doi: 10.1186/s13053-022-00237-x.
    • Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy.
    • Trivedi MS, Arber N, Friedman E, Garber JE, Holcomb K, Horowitz NS, Wright JD, Lee JJ, Vornik LA, Abutaseh S, Castile T, Sauter ER, Dimond E, Heckman-Stoddard BM, House M, Samimi G, Brown PH, Crew KD.
    • Cancer Prev Res (Phila). 2022 Aug 24:OF1-OF6. doi: 10.1158/1940-6207.CAPR-22-0051. Epub ahead of print.
    • Commentary

    Related:

    Identifier: NCT03382574: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy. (ClinicalTrials.gov)

    • Axillary Lymphadenopathy associated with COVID-19 vaccination: updates and recommendations.
    • Schwaner SL.
    • J Radiol Nurs. 2022 Aug 19. doi: 10.1016/j.jradnu.2022.08.006. Epub ahead of print.
    • GeneHome - a Novel Model to Deliver Care to Individuals with Genetic Predisposition to Cancer.
    • Nocera Zachariah N, Lee MC, Chang MD, Moore C, Wang X.
    • Cancer Control. 2022 Jan-Dec [First published 2022 Aug 17];29:10732748221109951. doi: 10.1177/10732748221109951.
    • A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: "So many little, little traumas could have been avoided".
    • Warner NZ, Groarke A.
    • BMC Health Serv Res. 2022 Aug 6;22(1):1007. doi: 10.1186/s12913-022-08372-w.
    • Decision thresholds with genetic testing.
    • Felder S.
    • Eur J Health Econ. 2022 Aug;23(6):1071-1078. doi: 10.1007/s10198-021-01410-0. Epub 2021 Dec 2.
    • Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.
    • Lourenção M, Simões Correa Galendi J, Galvão HCR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, de Oliveira JHC, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jul 11;12:951310. doi: 10.3389/fonc.2022.951310.
    • Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.
    • Bommer C, Lupatsch J, Bürki N, Schwenkglenks M.
    • Eur J Health Econ. 2022 Jul;23(5):807-821. doi: 10.1007/s10198-021-01396-9. Epub 2021 Nov 12.
    • Advocating for equitable management of hereditary cancer syndromes.
    • Caffrey RG.
    • J Genet Couns. 2022 Jun;31(3):584-589. doi: 10.1002/jgc4.1548. Epub 2022 Jan 14.
    • Commentary
    • How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
    • Kwong A, Ho CYS, Shin VY, Au CH, Chan TL, Ma ESK.
    • BMC Med Genomics. 2022 May 31;15(1):122. doi: 10.1186/s12920-022-01270-4.
    • Breast cancer risk for transgender men with inherited mutations.
    • [No author given]
    • FORCE. XRAY. 2022 May 19.

    Related:

    Commentary:

    BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.

    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Related:

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.
    • Simões Corrêa Galendi J, Kautz-Freimuth S, Stock S, Müller D.
    • Cancers (Basel). 2022 Mar 31;14(7):1786. doi: 10.3390/cancers14071786.
    • Neurofibromatosis 1 in the setting of dual diagnosis: Diagnostic and management conundrums.
    • Muthusamy K, El-Jabali A, Ongie LJ, Dhamija R, Babovic-Vuksanovic D.
    • Am J Med Genet A. 2022 Mar;188(3):911-918. doi: 10.1002/ajmg.a.62575. Epub 2021 Nov 19.
    • Case report
    • Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.
    • Li J, Jia Z, Zhang M, Liu G, Xing Z, Wang X, Huang X, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Front Oncol. 2022 Jan 10;11:763161. doi: 10.3389/fonc.2021.763161.
    • BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.
    • Jaber C, Ralph O, Hamidian Jahromi A.
    • Plast Reconstr Surg Glob Open. 2022 Jan 10;10(1):e4012. doi: 10.1097/GOX.0000000000004012.

    Related:

    Research news: Breast cancer risk for transgender men with inherited mutations. (FORCE. XRAY)

    • HerediCaRe: Dokumentations- und IT-Lösung eines spezialisierten Registers für erblichen Brust- und Eierstockkrebs [HerediCaRe: Documentation and IT Solution of a Specialized Registry for Hereditary Breast and Ovarian Cancer].
    • Engel C, Wieland K, Zachariae S, Bucksch K, Enders U, Schoenwiese U, Yahiaoui-Doktor M, Keupp K, Waha A, Hahnen E, Remy R, Ernst C, Loeffler M, Schmutzler RK.
    • Gesundheitswesen. 2021 Nov;83(S 01):S12-S17. German. doi: 10.1055/a-1658-0313. Epub 2021 Nov 3.
    • Impact of Variant Reclassification in Cancer Predisposition Genes on Clinical Care.
    • Chiang J, Chia TH, Yuen J, Shaw T, Li ST, Binte Ishak ND, Chew EL, Chong ST, Chan SH, Ngeow J.
    • JCO Precis Oncol. 2021 Nov;5:577-584. doi: 10.1200/PO.20.00399.
    • Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis.
    • Michaan N, Leshno M, Cohen Y, Safra T, Peleg-Hasson S, Laskov I, Grisaru D.
    • Reprod Biol Endocrinol. 2021 Oct 8;19(1):153. doi: 10.1186/s12958-021-00827-9.
    • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    • Simões Corrêa Galendi J, Vennedey V, Kentenich H, Stock S, Müller D.
    • Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
    • Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.
    • Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z, Huang X, Liu G, Zhang M, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2.
    • Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome.
    • Wright JD, Silver ER, Tan SX, Hur C, Kastrinos F.
    • JAMA Netw Open. 2021 Sep 1;4(9):e2123616. doi: 10.1001/jamanetworkopen.2021.23616.

    Related:

    Commentary:

    Exploring Gene-Specific Guidelines for Risk Management of Gynecological Cancer in Lynch Syndrome

    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • A rare case of breast cancer in a transgender woman.
    • Sieberg R, Soriano K, Zuurbier R.
    • Radiol Case Rep. 2021 Aug 26;16(11):3285-3288. doi: 10.1016/j.radcr.2021.07.052.
    • Liquid Biopsy Can Detect Brca2 Gene Variants In Female Dogs With Mammary Neoplasia.
    • de Oliveira JR, Colombo J, Gonçalves FM, de Carvalho LAL, Costa DS, Henrique T, Novais AA, Moscheta-Pinheiro MG, de Almeida Chuffa LG, Coutinho LL, Santana ÁE, de Campos Zuccari DAP.
    • Vet Comp Oncol. 2021 Jul 30. doi: 10.1111/vco.12758. Epub ahead of print.
    • Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening.
    • Pan IW, Oeffinger KC, Shih YT.
    • J Natl Cancer Inst. 2021 Jul 28:djab150. doi: 10.1093/jnci/djab150. Epub ahead of print.

    Press: Out-of-Pocket Costs for MRI Breast Cancer Screening Hitting More Women. (Medscape)

    • Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.
    • Ben David MA, Evron E, Rasco AF, Shai A, Corn BW.
    • Cancers (Basel). 2021 May 30;13(11):2694. doi: 10.3390/cancers13112694.
    • Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks.
    • Meier F, Harney A, Rhiem K, Neusser S, Neumann A, Braun M, Wasem J, Huster S, Dabrock P, Schmutzler RK.
    • Recent Results Cancer Res. 2021 [First Online: 22 May 2021];218:47-66. doi: 10.1007/978-3-030-63749-1_5.
    • eBook chapter
    • Should the BCRA1/2-mutations healthy carriers be valid candidates for hematopoietic stem cell donation?
    • Fresa A, Sica S.
    • Hered Cancer Clin Pract. 2021 Apr 1;19(1):22. doi: 10.1186/s13053-021-00179-w.
    • Sleep and circadian rhythm disruption is corrected by lithium in a case of bipolar disorder with familial BRCA1 mutation.
    • Federoff M, McCarthy MJ.
    • Bipolar Disord. 2021 Feb;23(1):101-103. doi: 10.1111/bdi.13014. Epub 2020 Oct 28.
    • Case report
    • Estimation of healthcare-related charges in women with BRCA mutations and breast cancer.
    • Biskupiak J, Unni S, Telford C, Yoo M, Ye X, Deka R, Brixner D, Stenehjem D.
    • BMC Health Serv Res. 2021 Jan 13;21(1):58. doi: 10.1186/s12913-020-06038-z.
    • Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto.
    • Cardoso F, MacNeill F, Penault-Llorca F, Eniu A, Sardanelli F, Nordström EB, Poortmans P.
    • Breast. 2021 Jan 2;55:128-135. doi: 10.1016/j.breast.2020.12.010. Epub ahead of print.
    • Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.
    • Qin N, Wang Z, Liu Q, Song N, Wilson CL, Ehrhardt MJ, Shelton K, Easton J, Mulder H, Kennetz D, Edmonson MN, Rusch MC, Downing JR, Hudson MM, Nichols KE, Zhang J, Robison LL, Yasui Y.
    • J Clin Oncol. 2020 Jun 4:JCO1902760. doi: 10.1200/JCO.19.02760. Epub ahead of print.

    Related:

    Research news: Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type. (GenomeWeb)

    • Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers.
    • Singh AK, Yu X.
    • Trends Cancer. 2020 Apr 23. pii: S2405-8033(20)30105-9. doi: 10.1016/j.trecan.2020.03.004. [Epub ahead of print]
    • Review, Commentary
    • Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control.
    • Widschwendter M, Dubeau L.
    • Cancers (Basel). 2020 Feb 27;12(3). pii: E547. doi: 10.3390/cancers12030547.
    • Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.
    • Petelin L, Hossack L, Shanahan M, Mitchell G, Liew D, James PA, Trainer AH.
    • Genet Med. 2020 Jan 30. doi: 10.1038/s41436-020-0751-3. [Epub ahead of print]
    • Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing.
    • Mikkelsen RB, Frederiksen HRS, Gjerris M, Holst B, Hyttel P, Luo Y, Freude K, Sandøe P.
    • CRISPR J. 2019 Dec;2(6):362-369. doi: 10.1089/crispr.2019.0024.
    • Commentary
    • Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis.
    • Ben-David MA, Corn BW, Evron E, Goldberg H, Pfeffer RM, Abdah-Bortnyak R, Matceyevsky D, Weinstein Y, Golan O, Sklair-Levy M.
    • Breast. 2019 Nov 6;49:70-73. doi: 10.1016/j.breast.2019.10.011. [Epub ahead of print]
    • Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?
    • Sawczuk B, Maciejczyk M, Sawczuk-Siemieniuk M, Posmyk R, Zalewska A, Car H.
    • Cancers (Basel). 2019 Oct 8;11(10). pii: E1501. doi: 10.3390/cancers11101501.
    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
    • Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.
    • Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3. doi: 10.1016/j.urolonc.2019.06.015. [Epub ahead of print]
    • Trans-counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants.
    • Sacca RE, Koeller DR, Rana HQ, Garber JE, Morganstern DE.
    • J Genet Couns. 2019 Jun;28(3):708-716. doi: 10.1002/jgc4.1046. Epub 2019 Jan 24.
    • Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia - a single center analysis.
    • Sandner AS, Weggel R, Mehraein Y, Schneider S, Hiddemann W, Spiekermann K.
    • PLoS One. 2019 Apr 18;14(4):e0215453. doi: 10.1371/journal.pone.0215453. eCollection 2019.
    • Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment.
    • Poortmans PMP, Kaidar-Person O.
    • Ann Oncol. 2019 Mar 1;30(3):348-350. doi: 10.1093/annonc/mdz014.
    • Research news, Editorial
    • Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
    • Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.
    • Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.

    Related:

    Editorial:

    Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?

    • Genetic variation and radiation quality impact cancer promoting cellular phenotypes in response to HZE exposure.
    • Sridharan DM, Enerio S, Wang C, LaBarge MA, Stampfer MR, Pluth JM.
    • Life Sci Space Res (Amst). 2019 Feb;20:101-112. doi: 10.1016/j.lssr.2018.10.002. Epub 2018 Oct 21.
    • Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    • Hoskins P, Eccleston A, Hurry M, Dyer M.
    • Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061-7. doi: 10.1016/j.ygyno.2019.01.018. [Epub ahead of print]
    • Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
    • Autier P.
    • JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6501. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply.

    Original research:

    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

    • [Additional non-contraceptive effects of contraception: CNGOF Contraception Guidelines].
    • Amat L, Bulach A, Leclercq M, Mesrine S, Scheffler F, Sperandeo D, Scheffler M.
    • Gynecol Obstet Fertil Senol. 2018 Dec;46(12):883-888. doi: 10.1016/j.gofs.2018.10.013. Epub 2018 Nov 7.
    • Review, [Article in French]
    • Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
    • Pashayan N, Morris S, Gilbert FJ, Pharoah PDP.
    • JAMA Oncol. 2018 Nov 1;4(11):1504-1510. doi: 10.1001/jamaoncol.2018.1901.

    Related:

    Editorial:

    Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine.

    Audio Interview: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening. (JAMA Oncology)

    Press: Breast Cancer Screening Only for Women at Higher Risk. (Medscape)

    Letter, Comment:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply.

    • Breast cancer in transgender patients: A systematic review. Part 1: Male to female.
    • Hartley RL, Stone JP, Temple-Oberle C.
    • Eur J Surg Oncol. 2018 Oct;44(10):1455-1462. doi: 10.1016/j.ejso.2018.06.035. Epub 2018 Jul 25.
    • Review
    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.
    • McVeigh TP, Wiggins J, Ward S, Kemp Z, George AJ.
    • Clin Breast Cancer. 2018 Aug;18(4):282-288. doi: 10.1016/j.clbc.2017.10.015. Epub 2017 Oct 28.
    • Complex Medical Decision-Making for a Trans-Feminine Youth with a BRCA1 Mutation.
    • Wolf-Gould CS, Riley MR, Carswell JM.
    • LGBT Health. 2018 May/Jun;5(4):221-225. doi: 10.1089/lgbt.2017.0149.
    • Case report
    • A Trans-Feminine Youth with a BRCA1 Mutation: Case Study.
    • Wolf-Gould CS, Riley MR, Carswell JM.
    • LGBT Health. 2018 May/Jun;5(4):270-272. doi: 10.1089/lgbt.2017.0148. Epub 2018 May 11.
    • Letter, Case report
    • A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.
    • Scherr CL, Feuston JL, Nixon DM, Cohen SA.
    • J Genet Couns. 2018 Apr;27(2):439-445. doi: 10.1007/s10897-018-0222-z. Epub 2018 Feb 8.
    • An iPhone Application Intervention to Promote Surveillance Among Women with a BRCA Mutation: Pre-intervention Data.
    • Cohen SA, Scherr CL, Nixon DM.
    • J Genet Couns. 2018 Apr;27(2):446-456. doi: 10.1007/s10897-018-0224-x. Epub 2018 Feb 10.
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • A15 Blood cadmium (Cd) level as a marker of cancer risk in BRCA1 (+) prospective cohort study.
    • Marciniak W, Derkacz R, Baszuk P, Kuświk M, Kaczmarek K, Muszyńska M, Lener M, Huzarski T, Gronwald J, Oszurek O, Tołoczko-Grabarek A, Cybulski C, Dębniak T, Morawski A, Jakubowska A, Lubiński J.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A15. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • A16 Arsenic as a marker of cancer risk.
    • Derkacz R, Marciniak W, Baszuk P, Kuświk M, Kaczmarek K, Muszyńska M, Lener M, Huzarski T, Gronwald J, Oszurek O, Tołoczko-Grabarek A, Cybulski C, Dębniak T, Morawski A, Jakubowska A, Lubiński J.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A16. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting.
    • O'Leary MP, Goldner BS, Abboy S, Mercado PD, Plurad HY.
    • Fam Cancer. 2018 Jan;17(1):175-178. doi: 10.1007/s10689-017-0010-1.
    • Prophylaxis of hereditary breast cancer.
    • de Groot JS, van Diest PJ, Derksen PWB.
    • Aging (Albany NY). 2017 Dec 8;9(12):2453-2454. doi: 10.18632/aging.101342.
    • Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
    • Mazumder S, Johnson JM, Swank V, Dvorina N, Martelli E, Ko J, Tuohy VK.
    • Cancer Prev Res (Phila). 2017 Nov;10(11):612-624. doi: 10.1158/1940-6207.CAPR-17-0154.

    Related:

    Editorial:

    Targeting "Retired Antigens" for Cancer Immunoprevention.

    • [Entitlement to prophylactic treatment in cases of genetic predisposition for breast cancer : Interdisciplinary perspectives].
    • Meier F, Ried J, Harney A, Rhiem K, Neusser S, Neumann A, Wasem J, Schmutzler R, Huster S, Dabrock P.
    • Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Oct;60(10):1102-1108. doi: 10.1007/s00103-017-2608-8.
    • Review, [Article in German]
    • Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries.
    • Pokharel HP, Hacker NF, Andrews L.
    • Hered Cancer Clin Pract. 2017 Sep 18;15:12. doi: 10.1186/s13053-017-0072-y. eCollection 2017.
    • ['Healthy sick' or: How Genetic Risks Lever the Disease Concept of the Healthcare System].
    • Meier F, Ried J, Braun M, Dabrock P.
    • Gesundheitswesen. 2017 Aug;79(8-09):594-598. doi: 10.1055/s-0043-109862. Epub 2017 Jul 14.
    • English Abstract, [Article in German]
    • Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation.
    • Škerl P, Krajc M, Blatnik A, Novaković S.
    • Oncol Rep. 2017 Jul;38(1):279-282. doi: 10.3892/or.2017.5703. Epub 2017 Jun 6.
    • Case report
    • "The Absence Doubled?" Photo-Poetic Narratives of Prophylactic Mastectomy.
    • Bolaki S.
    • Lit Med. [2017 Spring;]35(1):1-26. doi: 10.1353/lm.2017.0000.
    • Commentary
    • Male transgender breast cancer patient shares his experience in NYT piece.
    • Lisa Rezende, Julie Huynh
    • FORCE. XRAYS. 2016 Dec 21.
    • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
    • Larouche G, Chiquette J, Plante M, Pelletier S, Simard J, Dorval M.
    • Can Assoc Radiol J. 2016 Nov;67(4):308-312. doi: 10.1016/j.carj.2015.12.003. Epub 2016 Jun 16.
    • A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
    • Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.
    • Isr Med Assoc J. 2016 Sep;18(9):549-552.

    Related:

    Editorial:

    Handling Individuals with High Cancer Risk: One Size Doesn't Fit All.

    • [Multidisciplinary team meetings settings on the management of women at high risk of inherited breast cancer. A French study].
    • Gillmann F, Cordier C, Taris N, Mathelin C, Maugard CM.
    • Bull Cancer. 2016 Jun;103(6):571-83. doi: 10.1016/j.bulcan.2016.03.006. Epub 2016 May 11.
    • [Article in French]
    • Addressing inherited predisposition for breast cancer in transplant recipients.
    • Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL.
    • J Surg Oncol. 2016 May;113(6):605-8. doi: 10.1002/jso.24193. Epub 2016 Feb 10.
    • Case report, Review
    • The Management of Breast Cancer Detected by Reduction Mammaplasty.
    • Carlson GW.
    • Clin Plast Surg. 2016 Apr;43(2):341-7. doi: 10.1016/j.cps.2015.12.001. Epub 2016 Jan 26.
    • Review
    • Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    • Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.
    • Fertil Steril. 2016 Mar;105(3):781-5. doi: 10.1016/j.fertnstert.2015.11.034. Epub 2015 Dec 14.
    • Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium.
    • Nakamura S, Kwong A, Kim SW, Iau P, Patmasiriwat P, Dofitas R, Aryandono T, Hu Z, Huang CS, Ginsburg O, Rashid MU, Sarin R, Teo SH.
    • Public Health Genomics. [2016 Jan;]19(1):53-60. doi: 10.1159/000441714. Epub 2015 Nov 18.
    • The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment.
    • Basse C, Arock M.
    • Int J Cancer. 2015 Dec 15;137(12):2785-94. doi: 10.1002/ijc.29347. Epub 2014 Dec 1.
    • Review
    • Hereditary Cancer, Insurance, and Your Legal Rights.
    • Anya Prince.
    • FORCE. Be Empowered Webinars. 2015 Nov 18.
    • Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation.
    • Howe R, Miron-Shatz T, Hanoch Y, Omer ZB, O'Donoghue C, Ozanne EM.
    • J Genet Couns. 2015 Oct;24(5):744-51. doi: 10.1007/s10897-014-9803-7. Epub 2014 Dec 18.
    • Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge.
    • Dupont SC, Boughey JC, Jimenez RE, Hoskin TL, Hieken TJ.
    • Surgery. 2015 Oct;158(4):988-95. doi: 10.1016/j.surg.2015.05.020. Epub 2015 Aug 1.
    • BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
    • Sopik V, Phelan C, Cybulski C, Narod SA.
    • Clin Genet. 2015 May;87(5):411-8. doi: 10.1111/cge.12497. Epub 2014 Oct 21.
    • Review

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: article request

    Comment / Letter

    Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?

    Reply / Letter

    Response to Evans et al.

    • Prediction of breast cancer risk based on profiling with common genetic variants.
    • Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, Dudbridge F, Johnson N, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Couch FJ, Olson JE, Vachon C, Pankratz VS, Lambrechts D, Wildiers H, Van Ongeval C, van Limbergen E, Kristensen V, Grenaker Alnæs G, Nord S, Borresen-Dale AL, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Trentham-Dietz A, Newcomb P, Titus L, Egan KM, Hunter DJ, Lindstrom S, Tamimi RM, Kraft P, Rahman N, Turnbull C, Renwick A, Seal S, Li J, Liu J, Humphreys K, Benitez J, Pilar Zamora M, Arias Perez JI, Menéndez P, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Bogdanova NV, Antonenkova NN, Dörk T, Anton-Culver H, Neuhausen SL, Ziogas A, Bernstein L, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Cox A, Cross SS, Reed MW, Khusnutdinova E, Bermisheva M, Prokofyeva D, Takhirova Z, Meindl A, Schmutzler RK, Sutter C, Yang R, Schürmann P, Bremer M, Christiansen H, Park-Simon TW, Hillemanns P, Guénel P, Truong T, Menegaux F, Sanchez M, Radice P, Peterlongo P, Manoukian S, Pensotti V, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Brauch H, Brüning T, Ko YD, Sigurdson AJ, Doody MM, Hamann U, Torres D, Ulmer HU, Försti A, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Andrulis IL, Knight JA, Glendon G, Marie Mulligan A, Chenevix-Trench G, Balleine R, Giles GG, Milne RL, McLean C, Lindblom A, Margolin S, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Eilber U, Wang-Gohrke S, Hooning MJ, Hollestelle A, van den Ouweland AM, Koppert LB, Carpenter J, Clarke C, Scott R, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Brenner H, Arndt V, Stegmaier C, Karina Dieffenbach A, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Offit K, Vijai J, Robson M, Rau-Murthy R, Dwek M, Swann R, Annie Perkins K, Goldberg MS, Labrèche F, Dumont M, Eccles DM, Tapper WJ, Rafiq S, John EM, Whittemore AS, Slager S, Yannoukakos D, Toland AE, Yao S, Zheng W, Halverson SL, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, Simard J, Hall P, Easton DF, Garcia-Closas M.
    • J Natl Cancer Inst. 2015 Apr 8;107(5). pii: djv036. doi: 10.1093/jnci/djv036. Print 2015 May.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: BREVAGenplus- what is it?

    Editorial

    Breast cancer prevention in the era of precision medicine.

    Research News

    Genetic screening could improve breast cancer prevention, study finds.

    • [Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: Literature review.]
    • Jégu M, Der AS, Morcel K, Abadie C, Fritel X, Levêque J.
    • J Gynecol Obstet Biol Reprod (Paris). 2015 Jan;44(1):10-17. doi: 10.1016/j.jgyn.2014.10.011. Epub 2014 Nov 18.
    • Review, [Article in French]
    • Breast Cancer in Male-to-Female Transsexuals: Use of Breast Imaging for Detection.
    • Maglione KD, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, Sonnenblick EB.
    • AJR Am J Roentgenol. 2014 Dec;203(6):W735-40. doi: 10.2214/AJR.14.12723.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Cancer risks for transgender patient

    • Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations.
    • Garcia C, Lyon L, Littell RD, Powell CB.
    • Genet Med. 2014 Dec;16(12):896-902. doi: 10.1038/gim.2014.48. Epub 2014 May 22.
    • Serous adenocarcinoma of the ovary diagnosed during ultrasound evaluation for fertility preservation.
    • Hachem HE, Poulain M, Höher M, Fanchin R, Frydman R, Grynberg M.
    • Future Oncol. 2014 Oct;10(12):1907-12. doi: 10.2217/fon.14.82.
    • Case report
    • Hormonal and Surgical Treatment in Trans-Women with BRCA1 Mutations: A Controversial Topic.
    • Colebunders B, T'Sjoen G, Weyers S, Monstrey S.
    • J Sex Med. 2014 Oct;11(10):2496-9. doi: 10.1111/jsm.12628. Epub 2014 Jul 10.
    • Case report

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Cancer risks for transgender patient

    • Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
    • Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK.
    • Cancer Prev Res (Phila). 2014 Sep;7(9):896-905. doi: 10.1158/1940-6207.CAPR-13-0408. Epub 2014 Jun 20.
    • Use of fertility drugs and risk of ovarian cancer.
    • Diergaarde B, Kurta ML.
    • Curr Opin Obstet Gynecol. 2014 Jun;26(3):125-9. doi: 10.1097/GCO.0000000000000060.
    • Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem.
    • Tomao F, Lo Russo G, Spinelli GP, Tomao S.
    • Curr Opin Obstet Gynecol. 2014 Jun;26(3):130-7. doi: 10.1097/GCO.0000000000000067.
    • Review
    • Randomized Controlled Trial of “The Work” Meditation-Based Intervention for BRCA1/2 Mutation Carriers.
    • Lev-Ari Shahar, Landau Carla, Cohen-Mensfild Jiska, Friedman Eitan.
    • Journal of Alternative and Complementary Medicine. May 2014, 20(5): A59-A60; doi:10.1089/acm.2014.5155.abstract. 2014 May 7.
    • Establishing a program for individuals at high risk for breast cancer.
    • Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B.
    • J Cancer. 2013 Jul 1;4(5):433-46. doi: 10.7150/jca.6481. Print 2013.
    • A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.
    • Engel NJ, Gordon P, Thull DL, Dudley B, Herstine J, Jankowitz RC, Zorn KK.
    • Fam Cancer. 2012 Sep;11(3):419-27. doi: 10.1007/s10689-012-9530-x.
    • Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
    • Rhiem K, Pfeifer K, Schmutzler RK, Kiechle M.
    • Geburtshilfe Frauenheilkd. 2012 Sep;72(9):833-839.
    • Implementation and outcomes of a multidisciplinary high-risk breast cancer program: the William Beaumont Hospital experience.
    • Shah C, Berry S, Dekhne N, Lanni T, Lowry H, Vicini F.
    • Clin Breast Cancer. 2012 Jun;12(3):215-8. doi: 10.1016/j.clbc.2012.03.002. Epub 2012 Apr 14.